Prognostic significance of metastasis-associated protein S100A4 (Mts1) in prostate cancer progression and chemoprevention regimens in an autochthonous mouse model.

PURPOSE We recently showed that metastasis-promoting Mts1 gene (S100A4) and protein is overexpressed during progression of prostate cancer in humans. The purpose of this study was to assess the expression of S100A4 during autochthonous prostate cancer progression in transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Because oral consumption of green tea polyphenols (GTP) has been shown to inhibit metastasis and prostate cancer in TRAMP, we further assessed the significance of S100A4 during chemoprevention regimen. EXPERIMENTAL DESIGN Male TRAMP mice 8 weeks of age were equally divided into two groups. A freshly prepared 0.1% GTP solution in tap water was supplied thrice a week to experimental animals as the sole source of drinking fluid for 24 weeks, whereas the control group of animals received the same tap water throughout the experiment. The animals were sacrificed at 0, 8, 16, and 24 weeks of GTP feeding and were analyzed for S100A4 and E-cadherin. Additional untreated and treated nontransgenic controls were also included in the study. RESULTS With the progression of age and prostate cancer growth in TRAMP mice, an increase in the expression of S100A4 at mRNA and protein level in dorsolateral prostate, but not in nontransgenic mice, occurred. GTP feeding to TRAMP mice resulted in marked inhibition of prostate cancer progression, which was associated with reduction of S100A4 and restoration of E-cadherin. CONCLUSIONS S100A4 represents a promising marker for prostate cancer progression and could be employed as a biomarker in chemoprevention regimens.

[1]  J. Nesland,et al.  Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma , 2004, Modern Pathology.

[2]  I. Thompson,et al.  Update on chemoprevention of prostate cancer , 2004, Current opinion in urology.

[3]  J. Lewin,et al.  Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.

[4]  Jun Wang,et al.  Genistein alters growth factor signaling in transgenic prostate model (TRAMP) , 2004, Molecular and Cellular Endocrinology.

[5]  V. Adhami,et al.  Tea Beverage in Chemoprevention of Prostate Cancer: A Mini-Review , 2003, Nutrition and cancer.

[6]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[7]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[8]  K. B. Pedersen,et al.  Expression of S100A4, E-cadherin, α- and β-catenin in breast cancer biopsies , 2002, British Journal of Cancer.

[9]  Cody Schrank,et al.  American Cancer Society , 2005 .

[10]  J. Lewin,et al.  Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Donato,et al.  S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. , 2001, The international journal of biochemistry & cell biology.

[12]  N. Ohuchi,et al.  The loss of E-cadherin, α- and β-catenin expression is associated with metastasis and poor prognosis in invasive breast cancer , 2001 .

[13]  I. Thompson,et al.  Association of African-American ethnic background with survival in men with metastatic prostate cancer. , 2001, Journal of the National Cancer Institute.

[14]  C. Heizmann,et al.  Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. MacLennan,et al.  Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice , 2000 .

[16]  M. Steiner,et al.  Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. , 2000, Cancer research.

[17]  C. Heizmann,et al.  Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. , 2000, International journal of oncology.

[18]  J. Winstanley,et al.  Comparison of the metastasis‐inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer , 2000, International journal of cancer.

[19]  J. Winstanley,et al.  Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. , 2000, Cancer research.

[20]  H. Höfler,et al.  Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility , 1999, Oncogene.

[21]  C. Heizmann,et al.  Supratentorial Pilocytic Astrocytomas, Astrocytomas, Anaplastic Astrocytomas and Glioblastomas are Characterized by a Differential Expression of S100 Proteins , 1999, Brain pathology.

[22]  R. Barraclough.  Calcium-binding protein S100A4 in health and disease. , 1998, Biochimica et biophysica acta.

[23]  W. Satariano,et al.  Cause of death in men diagnosed with prostate carcinoma , 1998, Cancer.

[24]  D. Atar,et al.  Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium. , 1998, Journal of cell science.

[25]  Roger Barraclough,et al.  Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells , 1998, Oncogene.

[26]  G V Sherbet,et al.  S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. , 1998, Anticancer research.

[27]  C. Heizmann,et al.  Expression pattern of S100 calcium‐binding proteins in human tumors , 1996, International journal of cancer.

[28]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[29]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Gerretsen,et al.  L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives , 1994 .

[31]  M. Grigorian,et al.  The mts1 gene and control of tumor metastasis. , 1993, Gene.

[32]  D W SMITHERS,et al.  Clinical Cancer Research , 1941, Lancet.

[33]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[34]  Tajamul Hussain,et al.  Differential expression of S100A2 and S100A4 during progression of human prostate adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Heizmann.  The multifunctional S100 protein family. , 2002, Methods in molecular biology.

[36]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[37]  N. Dubrawsky.  Cancer statistics , 2022 .